DS
Therapeutic Areas
IcanoMAB Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HER2newC apoptosis inducer | Early Breast Cancer (neoadjuvant) | Pre-clinical |
| CD40 agonist | Immuno-Oncology (Solid Cancers) / Severe Infectious Diseases | Pre-clinical |
| IL-1R7 antagonist | Acute Inflammatory Diseases (Covid-19 ARDS/CRS, MAS, SJIA, IBD, Gout) | Pre-clinical |